Drug

Sichuan Biokin's Iza‑Bren Combination Therapy Clinical Trial Application Approved by NMPA – EGFR×HER3 Bispecific ADC Advances with Radiotherapy in Locally Advanced Unresectable HNSCC
ADC / XDCBiokin Pharmaceutical

Sichuan Biokin’s Iza‑Bren Combination Therapy Clinical Trial Application Approved by NMPA – EGFR×HER3 Bispecific ADC Advances with Radiotherapy in Locally Advanced Unresectable HNSCC

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the clinical trial application (CTA) for combination therapy with its self-developed izalontamab brengitecan (BL‑B01D1 / iza‑bren) — described by the company…

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Genentech Reports One‑Year Phase III Data for Vamikibart in Uveitic Macular Edema – MEERKAT and SANDCAT Support Rapid, Sustained Vision Improvement

Genentech Reports One‑Year Phase III Data for Vamikibart in Uveitic Macular Edema – MEERKAT and SANDCAT Support Rapid, Sustained Vision Improvement

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ADC / XDCClinical trial approval / initiation

Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

J&J's AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
CancerJ&J

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Abbisko TherapeuticsHKG: 2256

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Zelgen's Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
Market launchSHA: 688266

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Show More